Prostaglandin E2 EP1 receptors: Downstream effectors of COX-2 neurotoxicity

Nature Medicine

Volumn 12, Issue 2, 2006, Pages 225-229

  Kawano, Takayuki ^a   Anrather, Josef ^a   Zhou, Ping ^a   Park, Laibaik ^a   Wang, Gang ^a   Frys, Kelly A ^a   Kunz, Alexander ^a   Cho, Sunghee ^a   Orio, Marcello ^a   Iadecola, Costantino ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; CALCIUM ION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIZOCILPINE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; SC 51089; UNCLASSIFIED DRUG; CALCIUM; KAINIC ACID; N METHYLASPARTIC ACID; NEUROTOXIN; PROSTANOID RECEPTOR EP1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; EXCITOTOXICITY; GENE INACTIVATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SODIUM CALCIUM EXCHANGE; ANIMAL; BRAIN; BRAIN ISCHEMIA; C57BL MOUSE; CELL DEATH; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOUSE MUTANT; NERVE CELL; PATHOLOGY;

ANIMALIA;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CALCIUM; CELL DEATH; CYCLOOXYGENASE 2; DINOPROSTONE; KAINIC ACID; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; N-METHYLASPARTATE; NEURONS; NEUROTOXINS; RECEPTORS, PROSTAGLANDIN E;

EID: 32244432739     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1362     Document Type: Article

References (30)

1. Simmons, D.L., Botting, R.M. & Hla, T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56, 387-437 (2004).
2. Hata, A.N. & Breyer, R.M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103, 147-166 (2004).
3. Minghetti, L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 63, 901-910 (2004).
4. Chen, C. & Bazan, N.G. Lipid signaling: sleep, synaptic plasticity, and neuroprotection. Prostaglandins Other Lipid Mediat. 77, 65-76 (2005).
5. Niwa, K., Araki, E., Morham, S.G., Ross, M.E. & Iadecola, C. Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J. Neurosci. 20, 763-770 (2000).
6. FitzGerald, G.A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2, 879-890 (2003).
7. Topol, E.J. Failing the public health - rofecoxib, Merck, and the FDA. N. Engl. J. Med. 351, 1707-1709 (2004).
8. Manabe, Y. et al. Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Ann. Neurol. 55, 668-675 (2004).
9. Carlson, N.G. Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase-2 inhibitor APHS can be reversed by a prostanoid. J. Neurosci. Res. 71, 79-88 (2003).
10. Bilak, M. et al. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann. Neurol. 56, 240-248 (2004).
11. McCullough, L. et al. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J. Neurosci. 24, 257-268 (2004).
12. Ahmad, A.S., Ahmad, M., de Brum-Fernandes, A.J. & Dore, S. Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Res. 1066, 71-77 (2005).
13. Suganami, T. et al. Role of prostaglandin E receptor EP1 subtype in the development of renal injury in genetically hypertensive rats. Hypertension 42, 1183-1190 (2003).
14. Hallinan, E.A. et al. Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE2 antagonist, and its analogs. J. Med. Chem. 39, 609-613 (1996).
15. Audoly, L.P. et al. Identification of specific EP receptors responsible for the hemodynamic effects of PGE2. Am. J. Physiol. 277, H924-H930 (1999).
16. Nogawa, S., Zhang, F., Ross, M.E. & Iadecola, C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci. 17, 2746-2755 (1997).
17. Caggiano, A.O. & Kraig, R.P. Prostaglandin E receptor subtypes in cultured rat microglia and their role in reducing lipopolysaccharide-induced interleukin-1β production. J. Neurochem. 72, 565-575 (1999).
18. Ladeby, R. et al. Microglial cell population dynamics in the injured adult central nervous system. Brain Res. Brain Res. Rev. 48, 196-206 (2005).
19. Iadecola, C. et al. Reduced susceptibility to ischemic brain injury and NMDA-mediated neurotoxicity in cyclooxygenase-2 deficient mice. Proc. Natl. Acad. Sci. USA 98, 1294-1299 (2001).
20. Sattler, R. & Tymianski, M. Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol. Neurobiol. 24, 107-129 (2001).
21. Choi, D.W. Neurodegeneration: cellular defences destroyed. Nature 433, 696-698 (2005).
22. Funk, C.D. et al. Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J. Biol. Chem. 268, 26767-26772 (1993).
23. Randall, R.D. & Thayer, S.A. Glutamate-induced calcium transient triggers delayed calcium overload and neurotoxicity in rat hippocampal neurons. J. Neurosci. 12, 1882-1895 (1992).
24. 2+ overload indicates early neuronal injury which precedes staining with viability indicators. Brain Res. 607, 319-323 (1993).
25. Khodorov, B. Glutamate-induced deregulation of calcium homeostasis and mitochondrial dysfunction in mammalian central neurones. Prog. Biophys. Mol. Biol. 86, 279-351 (2004).
26. + exchanger in excitotoxicity. Cell 120, 275-285 (2005).
27. 2+ exchanger: from molecular biology to therapeutic perspectives. Pharmacol. Rev. 56, 633-654 (2004).
28. 2+ concentration after a toxic glutamate treatment of the nerve cell culture. FEBS Lett. 324, 271-273 (1993).
29. +. Mol. Pharmacol. 56, 619-632 (1999).
30. Cho, S. et al. The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J. Neurosci. 25, 2504-2512 (2005).